Mankhwala Atsopano Ogwiritsa Ntchito Mankhwala Othandizira Zotupa Zapamwamba Zolimba

Written by mkonzi

Nuvation Bio Inc. lero yalengeza kuti US Food and Drug Administration (FDA) yachotsa ntchito yake yofufuza mankhwala atsopano (IND) kuti iwunike NUV-868, BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor, chifukwa chithandizo cha zotupa zolimba kwambiri, kuphatikizapo khansa ya m'mawere, khansa ya m'mawere, khansa ya m'mawere ya metastatic castration (mCRPC), ndi khansa ya m'mawere itatu (TNBC).

Sangalalani, PDF ndi Imelo

"Kuloledwa kwa pulogalamu yathu ya IND ya NUV-868 ndichinthu chofunikira kwambiri ku Nuvation Bio chifukwa ndi chizindikiro chachinayi cha IND m'miyezi 14 yapitayi kudutsa njira yathu yozama yamankhwala a khansa omwe akutsata mitundu ingapo ya zotupa," atero a David Hung, MD, woyambitsa. , Purezidenti, ndi wamkulu wamkulu wa Nuvation Bio. "Timalimbikitsidwa ndi kusankha komanso kulolera bwino komwe kukuwonetsedwa ndi NUV-868 m'maphunziro achipatala, ndipo tikuyembekeza kupititsa patsogolo pulogalamuyi kukhala gawo loyamba lachitukuko chapakati pa 1."

NUV-868 imalepheretsa BRD4, yomwe ndi membala wofunikira wa banja la BET lomwe limayang'anira mapuloteni omwe amawongolera kukula ndi kusiyanitsa kwa chotupa. NUV-868 idapangidwa kuti ikhale yosankha kwambiri BD2 kuposa BD1 poyesa kupewa zoletsa zoletsa zoletsa za BRD4 inhibitors monga m'mimba (GI) ndi poizoni wa m'mafupa. Maphunziro a preclinical awonetsa kuti NUV-868 ndiyosankha nthawi pafupifupi 1,500 ku BD2 kuposa BD1. Ma inhibitors osasankha a BD1/2 omwe ali pachitukuko amalumikizidwa ndi zovuta zololera, mwina chifukwa choletsa kwambiri BD1.

Ndi chilolezo cha IND iyi ya NUV-868 mu zotupa zolimba zapamwamba, Nuvation Bio ikhala ikuyambitsa kafukufuku wa Phase 1/2 wa NUV-868 ngati monotherapy komanso kuphatikiza ndi olaparib kapena enzalutamide mumitundu ingapo ya chotupa. Protocol iyi (NUV-868-01) iyamba ndi kafukufuku wowonjezereka wa mlingo wa Phase 1 kwa odwala chotupa olimba kwambiri. Kafukufuku wa Phase 1b adzayambika kuwunika NUV-868 kuphatikiza ndi olaparib mu khansa ya ovari yomwe idachiritsidwa kale, khansa ya kapamba, mCRPC, ndi odwala a TNBC komanso kuphatikiza enzalutamide kwa odwala mCRPC otsatiridwa ndi kafukufuku wa Phase 2b kuti apitilize kufufuza chitetezo ndi mphamvu. kamodzi kovomerezeka kwa Phase 2 kuphatikiza mlingo watsimikiziridwa. Kafukufuku wa Phase 2 monotherapy adzayambikanso mwa odwala a mCRPC komanso kuti afufuzenso chitetezo ndi mphamvu.

Sangalalani, PDF ndi Imelo

Ponena za wolemba

mkonzi

Mkonzi wamkulu wa eTurboNew ndi Linda Hohnholz. Amakhala ku eTN HQ ku Honolulu, Hawaii.

Siyani Comment

eTurboNews | | Mbiri ya TravelIndustry